m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00152)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
XIST
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
YTH domain-containing protein 1 (YTHDC1) [READER]
Representative RNA-seq result indicating the expression of this target gene regulated by YTHDC1 | ||
Cell Line | MOLM-13 cell line | Homo sapiens |
Treatment: shYTHDC1 MOLM13 cells
Control: shControl MOLM13 cells
|
GSE178859 | |
Regulation |
|
logFC: -9.25E-01 p-value: 3.66E-11 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | RBM15 and WTAP are required for X inactive specific transcript (XIST)-mediated silencing, are co-localized, and potentially interact with XIST RNA. YTHDC1 is the m6A reader of XIST and is required for XIST function. | |||
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RIP-seq result supporting the interaction between XIST and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 2.31E+00 | GSE60213 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 regulates ossification of the posterior longitudinal ligament via the lncRNA X inactive specific transcript (XIST)/miR-302a-3p/USP8 axis. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Ossification of spinal ligaments | ICD-11: FA83 | ||
Pathway Response | Ubiquitin mediated proteolysis | hsa04120 | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | Human primary ligament fibroblasts (Ligaments were dissected from a non-ossified site) | |||
Methyltransferase-like 14 (METTL14) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | In colorectal cancer, knockdown of METTL14 substantially abolished m6A level of X inactive specific transcript (XIST) and augmented XIST expression. m6A-methylated XIST was recognized by YTHDF2, a m6A reader protein, to mediate the degradation of XIST. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Cell Process | Tumorigenicity and metastasis | |||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For liver metastasis model, mice were anaesthetized and an incision was made through the skin and peritoneum to expose the spleen. 1 × 106 HCT116 cells were injected into the spleen (n = 4 each group). | |||
RNA-binding motif protein 15 (RBM15) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | RBM15 and WTAP are required for X inactive specific transcript (XIST)-mediated silencing, are co-localized, and potentially interact with XIST RNA. YTHDC1 is the m6A reader of XIST and is required for XIST function. | |||
Wilms tumor 1-associating protein (WTAP) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | RBM15 and WTAP are required for X inactive specific transcript (XIST)-mediated silencing, are co-localized, and potentially interact with XIST RNA. YTHDC1 is the m6A reader of XIST and is required for XIST function. | |||
YTH domain-containing family protein 2 (YTHDF2) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | In colorectal cancer, knockdown of METTL14 substantially abolished m6A level of X inactive specific transcript (XIST) and augmented XIST expression. m6A-methylated XIST was recognized by YTHDF2, a m6A reader protein, to mediate the degradation of XIST. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Cell Process | Tumorigenicity and metastasis | |||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For liver metastasis model, mice were anaesthetized and an incision was made through the skin and peritoneum to expose the spleen. 1 × 106 HCT116 cells were injected into the spleen (n = 4 each group). | |||
Colorectal cancer [ICD-11: 2B91]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | In colorectal cancer, knockdown of METTL14 substantially abolished m6A level of X inactive specific transcript (XIST) and augmented XIST expression. m6A-methylated XIST was recognized by YTHDF2, a m6A reader protein, to mediate the degradation of XIST. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Tumorigenicity and metastasis | |||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For liver metastasis model, mice were anaesthetized and an incision was made through the skin and peritoneum to expose the spleen. 1 × 106 HCT116 cells were injected into the spleen (n = 4 each group). | |||
Experiment 2 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | In colorectal cancer, knockdown of METTL14 substantially abolished m6A level of X inactive specific transcript (XIST) and augmented XIST expression. m6A-methylated XIST was recognized by YTHDF2, a m6A reader protein, to mediate the degradation of XIST. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Cell Process | Tumorigenicity and metastasis | |||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
HT29 | Colon cancer | Mus musculus | CVCL_A8EZ | |
LoVo | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | |
NCM460 | Normal | Homo sapiens | CVCL_0460 | |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
SW620 | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | |
In-vivo Model | For liver metastasis model, mice were anaesthetized and an incision was made through the skin and peritoneum to expose the spleen. 1 × 106 HCT116 cells were injected into the spleen (n = 4 each group). | |||
Ossification of spinal ligaments [ICD-11: FA83]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 regulates ossification of the posterior longitudinal ligament via the lncRNA X inactive specific transcript (XIST)/miR-302a-3p/USP8 axis. | |||
Responsed Disease | Ossification of spinal ligaments [ICD-11: FA83] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Ubiquitin mediated proteolysis | hsa04120 | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | Human primary ligament fibroblasts (Ligaments were dissected from a non-ossified site) | |||
References